Clinistem Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 07-12-2024
- Paid Up Capital ₹ 0.10 M
as on 07-12-2024
- Company Age 18 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2022)
- Profit -152.76%
(FY 2022)
- Ebitda -153.11%
(FY 2022)
- Net Worth -0.15%
(FY 2022)
- Total Assets -1.68%
(FY 2022)
About Clinistem Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Vikram Varanasi and Varanasi Reddy serve as directors at the Company.
- CIN/LLPIN
U24231KA2006PTC039713
- Company No.
039713
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Jun 2006
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Clinistem Life Sciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vikram Varanasi  | Director | 11-Nov-2022 | Current |
| Varanasi Reddy | Director | 20-Dec-2021 | Current |
Financial Performance and Corporate Structure Insights of Clinistem Life Sciences.
Clinistem Life Sciences Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 152.76% decrease in profit. The company's net worth dipped by a decrease of 0.15%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Clinistem Life Sciences?
In 2021, Clinistem Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Naturo Food And Fruit Products Private LimitedActive 38 years 1 monthVikram Varanasi and Varanasi Reddy are mutual person
- B.V. Reddy Enterprises Private LimitedActive 18 years 11 months
Vikram Varanasi and Varanasi Reddy are mutual person
- B V Reddy Transports Pvt LtdActive 41 years 9 months
Vikram Varanasi and Varanasi Reddy are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Clinistem Life Sciences?
Unlock and access historical data on people associated with Clinistem Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Clinistem Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Clinistem Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
